GW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 9 August, 2016

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Aug 2, 2016

LONDON, Aug. 02, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 9 August, 2016 its third quarter financial results for the period ending 30 June, 2016. GW will also host a conference call the same day at 8:30 a.m. EDT (1:30 p.m. BST). Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood-onset epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, LGS and Tuberous Sclerosis Complex. GW successfully commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries outside the United States. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc	
Stephen Schultz, VP Investor Relations (U.S.)
917 280 2424 / 401 500 6570
	
FTI Consulting (Media Enquiries)	
Ben Atwell / Simon Conway
+44 20 3727 1000

FleishmanHillard (U.S. Media)	
Paddi Hurley / Adam Silverstein
212 453 2382 / 917 697 9313

Recent News